Phase 3 data places retatrutides average weight reduction at approximately 28%, versus tirzepatides approximately 22.5% [2]
The Precision Peptide Genetic Test reveals predispositions in key peptide receptor and metabolic variants (GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, MC4R rs17782313) that may help provide context for medication selection conversations
However, talk to your doctor to know if you can use either of the medications or which one to buy
Meanwhile, research on the mechanism and efficacy of GLP-1R/GIPR dual agonists and GLP-1R/GIPR/GCGR triple agonists paves the way to a ground-breaking therapy specific for obesity, which suggests multi-target drugs may have more advantages than a single target
The primary lithogenic risk (gallbladder stasis) is eliminated once the gallbladder is removed
But I find in my anecdote, as you will, is it has been extremely safe